Thus, while gain-of-function mutations of PCSK9 increase the degradation of LDL receptors and enhance hypercholesterolemia, mutations in PCSK9 that diminish its function lower the levels of LDL cholesterol and produce a reduced risk of CVD [57]. The gene discussed is LDLR; the disease is familial hypercholesterolemia.